Tuesdays with Wilcockson: Doping on my mind, Part II
Tuesdays with Wilcockson
In last week’s column, I began to trace my journey in cycling from the 1960s, first as a racer then a writer, in connection with the sport’s escalating problems with illicit drugs. This week, I’ll continue the story from where I broke off, at the 1998 Tour de France, when the French team Festina was thrown out for organized doping. What the Festina Affair revealed was the degree to which EPO had transformed cycling in the worst possible way.
“Before EPO,” the 1988 Giro d’Italia champion Andy Hampsten told me, “we knew we were always racing against guys on drugs, but I don’t think those drugs gave them more of an advantage than the advantage we had knowing they’re gonna come crashing down. We didn’t lose energy worrying about what other people were doing; we just focused on ourselves, and we didn’t need to win every race.”
That “higher ground” attitude of Hampsten’s American team, Motorola, began to change in 1994. “There was a lot of grumbling on the team,” Hampsten said, “and we did get technical data from team doctor Massimo Testa because he’d talk to his colleagues on other teams. He was always straight with me. ‘Sure enough,’ he said, ‘if so-and-so who you raced with for eight years and you always dropped on the climbs, if that guy’s beating you now, his hematocrit is 15 points higher, and he’s gonna kill you in the mountains.’”
Because the new drug couldn’t be detected in anti-doping tests, no one knew for certain who was using EPO—and riders kept that secret to themselves. So, for the best part of a decade, until the Festina Affair, rumors were the only source of what was happening in the peloton. And rumors, without any corroborative evidence, were not things that professional journalists could write about. And when we did ask questions about doping those questions were sidestepped more often than not.
The situation began to change slightly in 1997 when the UCI mandated a maximum hematocrit level of 50 percent. Cyclists who tested above that level were not allowed to compete for at least two weeks, or until their red-blood-cell count returned to a “normal” level. But that couldn’t be translated into knowing a rider had used EPO. In any case, the new “health” regulation was a tiny deterrent because riders soon learned how to use portable centrifuges to test their own blood and keep the hematocrit level below 50—or so it was rumored.
The full extent of doping in the 1990s didn’t emerge until well after the Festina team was busted. First came the 1999 tell-all book, “Massacre à la Chaîne,” by soigneur Willy Voet who was fined and given a suspended prison sentence for his part in the Festina Affair. He wrote the book with French journalist Pierre Ballester, who worked for the Paris sports newspaper, L’Équipe, whose writers were just as shocked as everyone by the Festina Affair, the subsequent revelations in Voet’s book and the facts that later emerged in French courtrooms.
Testimonies at a December 2000 tribunal, which investigated the inner workings of the Festina team, showed that the French squad had engaged in organized doping since 1993. Prior to that year’s Tour de France, the tribunal’s report states, “the team riders who had yet to use EPO were growing impatient to get access to it several days before the start…. The main reason had to be that other teams were already administering this substance.”
Luc Leblanc, a French leader of the Festina team, admitted he used EPO in 1994 at the Vuelta a España and Tour de France, but he denied that EPO helped him win that year’s UCI world road title. But another witness, who worked for the team throughout the 1990s, testified that “all the Festina team riders at the 1994 world championships were given the same preparation: EPO with supplements. Luc did the same as everyone else.”
Riders entering the sport at that time were faced with a much more difficult decision than my racing peers had faced in the 1960s, when popping speed or getting injections of bull’s blood might have given riders a psychological edge but not much of a physical one. The dilemma in the ’90s for new professionals was to accept the use of EPO or risk never making the grade. That’s what Tyler Hamilton says made him begin doping in 1996, according to his new autobiography, “The Secret Race,” written with former Outside magazine journalist Dan Coyle.
Hamilton’s decision to use EPO coincided with his small American team, Montgomery-Bell, getting title sponsorship from the U.S. Postal Service that allowed them to start racing in Europe. By coincidence, I bumped into Hamilton on a flight back from Brussels to the U.S. in April 1996. I’d been reporting the spring classics for VeloNews, and Hamilton, then 25 and in his second year as a pro, told me about events he and the team had raced in the Netherlands, including his winning the Teleflex Toer stage race. Obviously, he didn’t say anything about EPO.
Like most other cycling journalists, I saw Hamilton—who majored in economics at the University of Colorado prior to turning pro—as part of a new generation of young riders from North America who were not polluted by Europe’s doping culture. Clean cut and quietly spoken, Hamilton seemed to be too smart to risk his health by doping, especially with the litany of dugs that appeared to be necessary to maximize the use of EPO.
As a sports journalist, you have to draw a fine line between writing about an athlete’s accomplishments and getting to know him (or her) through interviews and chats at races so that you can put those performances in perspective. Having had friendly working relationships with most of the sport’s successful modern “Anglo” riders—from pioneers Phil Anderson and Jonathan Boyer, followed by Steve Bauer, Greg LeMond, Robert Millar, Sean Kelly and Sean Yates, along with Andy Hampsten, Allan Peiper, Davis Phinney, Stephen Roche and many others—it seemed natural that I should do the same with the next wave, led by Lance Armstrong, Hamilton, George Hincapie, Chris Horner, Bobby Julich, Levi Leipheimer, Kevin Livingston, Fred Rodriguez and Christian Vande Velde.
It was difficult not to like all these guys. They were all young, intelligent and ambitious. And they were all making their mark in pro racing. When you did a one-on-one interview with those American cyclists you expected them to be truthful. That was the case in nearly all aspects of what they said about their lives, their training and their races—and you hoped it was true when they condemned doping and dopers.
Hamilton says in his book that he lied about his doping practices, even with his close friends and family. He was not the only one. I will write more about doping next week, but for now I’ll end with a quote from Brian Holm, now a highly regarded directeur sportif with Omega Pharma-Quick Step. The Dane wrote about his 13 years as a pro cyclist in his 2002 autobiography, in which he admitted to doping, just as Hamilton has today.
After Holm and many of his counterparts elaborated on their use of EPO at the Deutsche Telekom team, he said this to a Danish publication: “When I turned pro there was not that much talk about doping…and finally it was so normal that no-one thought it was illegal anymore. Many from my generation say that they were never doped, just as I said myself for a long time, because you thought that it really wasn’t doping or cheating. I actually think I could have passed a lie-detector test when I stopped my pro cycling career [in 1998], because I was convinced I was clean. It is only years later that you start realizing that it may not have been the case after all. It had become such a big part of your daily routine.”
Follow me on Twitter: @johnwilcockson
Image: John Pierce, Photosport International